Results 61 to 70 of about 13,819 (183)

Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients

Critical Care, 2019
Background The population pharmacokinetics of total and unbound posaconazole following intravenous administration has not yet been described for the critically ill patient population. The aim of this work was, therefore, to describe the total and unbound
Fekade B. Sime, Catherine J. Byrne, Suzanne Parker, Janine Stuart, Jenie Butler, Therese Starr, Saurabh Pandey, Steven C. Wallis, Jeffrey Lipman, Jason A. Roberts   +9 more
doaj   +1 more source

Economic Evaluation of Posaconazole Versus Standard Azole Therapy as Prophylaxis against Invasive Fungal Infections in Patients with Prolonged Neutropenia in Canada

Canadian Journal of Infectious Diseases and Medical Microbiology, 2012
INTRODUCTION: Posaconazole prophylaxis in high-risk neutropenic patients prevents invasive fungal infection (IFI). An economic model was used to assess the cost effectiveness of posaconazole from a Canadian health care system perspective.
Amir A Tahami Monfared, Amy K O’Sullivan, Coleman Rotstein, George Papadopoulos   +3 more
doaj   +1 more source

In Vitro Activities of Posaconazole (Sch 56592) Compared with Those of Itraconazole and Fluconazole against 3,685 Clinical Isolates of Candida spp. and Cryptococcus neoformans [PDF]

, 2001
Michael A. Pfaller, S. A. Messer, R. J. Hollis, Ronald N. Jones   +3 more
openalex   +1 more source

Isolation and in vitro susceptibility to amphotericin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus [PDF]

, 2001
Elias K. Manavathu, O. C. Abraham, Pranatharthi Chandrasekar   +2 more
openalex   +1 more source

Evaluation of Etest Method for Determining Posaconazole MICs for 314 Clinical Isolates of Candida Species [PDF]

, 2001
Michael A. Pfaller, S. A. Messer, K. Mills, Anne Bolmström, Ronald N. Jones   +4 more
openalex   +1 more source

Cost Analysis of the Use of Voriconazole, Posaconazole and Micafungin in the Primary Prophylaxis of Invasive Fungal Infections in Recipients of Allogeneic Hematopoietic Stem Cell Transplants

Journal of Health Economics and Outcomes Research, 2015
**Objectives:** Compare the cost of the primary prophylaxis of invasive fungal infections (IFI) with voriconazole, posaconazole, and micafungin in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) in hospitals of the National ...
Santiago Grau, Carlos Solano, Carol García-Vidal, Isidro Jarque, Jon A. Barrueta, Carmen Peral, Irene Rodríguez, Darío Rubio-Rodríguez, Carlos Rubio-Terrés   +8 more
doaj   +1 more source

Treatment ofScedosporium apiospermumBrain Abscesses with Posaconazole [PDF]

, 2002
Ingo K. Mellinghoff, Drew J. Winston, Geoffrey Mukwaya, Gary J. Schiller   +3 more
openalex   +1 more source

E-Test Method for Testing Susceptibilities of Aspergillus spp. to the New Triazoles Voriconazole and Posaconazole and to Established Antifungal Agents: Comparison with NCCLS Broth Microdilution Method [PDF]

, 2002
Ana Espinel‐Ingroff, Antonio Rezusta
openalex   +1 more source

Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals

International Journal of Infectious Diseases, 2019
Objectives: Novel formulations (gastro-resistant tablet and intravenous solution) of posaconazole (POS) have been approved in prophylaxis and therapy of invasive fungal diseases (IFDs).
Sebastian M. Heimann, Olaf Penack, Werner J. Heinz, Tobias Rachow, Gerlinde Egerer, Johanna Kessel, Annika Y. Claßen, Jörg Janne Vehreschild   +7 more
doaj  

Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults [PDF]

, 2003
Rachel Courtney, David Wexler, Elaine Radwanski, Josephine Lim, Mark Laughlin   +4 more
openalex   +1 more source